Ultragenyx Stock Today
| RARE Stock | USD 46.02 0.38 0.82% |
Performance0 of 100
| Odds Of DistressLess than 8
|
Ultragenyx is trading at 46.02 as of the 22nd of November 2024, a 0.82% down since the beginning of the trading day. The stock's lowest day price was 45.91. Ultragenyx has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for Ultragenyx are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of January 2014 | Category Healthcare | Classification Health Care |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. The company has 92.34 M outstanding shares of which 3.18 M shares are at this time shorted by private and institutional investors with about 5.09 trading days to cover. More on Ultragenyx
Moving together with Ultragenyx Stock
Moving against Ultragenyx Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Ultragenyx Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Erik Harris | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsUltragenyx can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ultragenyx's financial leverage. It provides some insight into what part of Ultragenyx's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ultragenyx (RARE) is traded on NASDAQ Exchange in USA. It is located in 60 Leveroni Court, Novato, CA, United States, 94949 and employs 1,276 people. Ultragenyx is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.28 B. Ultragenyx conducts business under Biotechnology sector and is part of Health Care industry. The entity has 92.34 M outstanding shares of which 3.18 M shares are at this time shorted by private and institutional investors with about 5.09 trading days to cover.
Ultragenyx currently holds about 542.8 M in cash with (474.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.75.
Check Ultragenyx Probability Of Bankruptcy
Ownership AllocationUltragenyx shows a total of 92.34 Million outstanding shares. The majority of Ultragenyx outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Ultragenyx to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Ultragenyx. Please pay attention to any change in the institutional holdings of Ultragenyx as this could imply that something significant has changed or is about to change at the company. Also note that roughly one million twenty-five thousand twenty-two invesors are currently shorting Ultragenyx expressing very little confidence in its future performance.
Check Ultragenyx Ownership Details
Ultragenyx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Rock Springs Capital Management Lp | 2024-06-30 | 1.9 M | |
| Millennium Management Llc | 2024-06-30 | 1.9 M | |
| Vestal Point Capital Lp | 2024-06-30 | 1.8 M | |
| Deutsche Bank Ag | 2024-06-30 | 1.8 M | |
| Baker Bros Advisors Lp | 2024-09-30 | 1.6 M | |
| Alliancebernstein L.p. | 2024-06-30 | 1.5 M | |
| Geode Capital Management, Llc | 2024-06-30 | 1.5 M | |
| Amvescap Plc. | 2024-06-30 | 1.3 M | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 1.1 M | |
| Vanguard Group Inc | 2024-09-30 | 9.9 M | |
| Blackrock Inc | 2024-06-30 | 5.6 M |
Ultragenyx Historical Income Statement
Ultragenyx Stock Against Markets
Ultragenyx Corporate Management
| Dennis Huang | Chief Technical Operations Officer and Sr. VP | Profile | |
| Theodore Huizenga | Corporate VP | Profile | |
| Arjun Natesan | Vice Research | Profile | |
| Vimal Srivastava | Senior Management | Profile | |
| Aaron Olsen | Senior Finance | Profile | |
| Paul JD | Vice Property | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.35) | Revenue Per Share 6.015 | Quarterly Revenue Growth 0.423 | Return On Assets (0.24) | Return On Equity (2.90) |
The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ultragenyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.